Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8
Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
Vasiliki Michalarea
Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies
Zev A. Wainberg
UCLA Medical Center-Santa Monica, Santa Monica, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)
Geoffrey Shapiro
Dana Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings
Todd M. Bauer
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers
Peter J O'Dwyer
Univ. of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870)
Roberto Pili
Indiana University, Indianapolis, IN, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: a phase I study in advanced solid tumor malignancies
Pamela N Munster
UCSF, San Francisco, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients
Nilofer Azad
Johns Hopkins University, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 8 of 8